






























































ie.	 the	 low-molecular	weight	<1KDa	 fraction	 in	biological	 samples,	 and	provides	a	 key	opportunity	 to	 advance	
neurosciences.	 Proton	 nuclear	magnetic	 resonance	 and	mass	 spectrometry	 are	 the	main	 analytical	 platforms	
used	 for	metabolic	 profiling,	 enabling	 detection	 and	 quantitation	 of	 a	wide	 range	 of	 compounds	 of	 particular	






central	 nervous	 system	 disorders.	 We	 highlight	 the	 potential	 of	 metabolic	 profiling	 for	 pharmacological	 and	
physiological	evaluation,	diagnosis	and	drug	therapy	monitoring	of	patients	affected	by	brain	disorders.	Finally,	
we	discuss	the	current	challenges	in	the	field,	including	the	development	of	systems	biology	and	pharmacology	







the	 diagnosis	 of	 CNS	 disease	 currently	 relies	 on	 compiling	 and	 grading	 a	 bunch	 of	 clinical	 symptoms.	 This	 is	
particularly	 valid	 when	 considering	 diseases	 of	 unknown	 etiology	 such	 as	 Alzheimer’s	 disease,	 schizophrenia	
(SCZ)	 or	 autism-spectrum	 disorders	 (ASD).	 One	 limitation	 of	 the	 currently	 available	 diagnosis	 tools	 is	 that,	 in	
most	 cases,	 the	 disease	 has	 to	 be	 well	 established	 for	 a	 clear	 diagnosis,	 even	 though	 early	 therapeutic	




reflect	 biological	 perturbations	 originating	 not	 only	 from	 collective	 internal	 variations	 in	 the	 genome,	
transcriptome	 and	 proteome,	 but	 also	 from	 environmental	 cues	 (diet,	 lifestyle,	 drug	 intake	 and	 toxicological	
exposure)	 (Nicholson	et	al.	2002).	Therefore,	an	emerging	 field	of	 investigation	of	 the	central	nervous	 system	
lies	 in	 the	 study	 and	 characterization	 of	 the	 metabolome:	 the	 entire	 complement	 of	 low-molecular	 weight	
chemicals	smaller	than	1	KDa	present	in	a	given	sample.	Among	known	metabolites	of	relevance	in	the	context	
of	 CNS	 study	 lie	 notably	 energetic	 substrates,	 neurotransmitters,	 neurochemicals	 and	 structural	 lipids.	 Large-
scale	 analysis	 of	 the	metabolome	 is	 achieved	 through	 the	 use	 of	metabolomics,	metabonomics	 or	metabolic	
profiling.	 Metabolomics	 was	 originally	 defined	 as	 the	 detailed	 qualitative	 and	 quantitative	 analysis	 of	 the	
metabolites	 present	 in	 complex	 biological	 samples	 (Oliver	 et	 al.	 1998),	 whilst	 metabonomics	 sought	 the	
measurement	of	the	global	metabolic	response	of	living	systems	to	pathological	stimuli	or	genetic	manipulation	
(Nicholson	et	al.	2002;	Nicholson	et	al.	1999).	Nowadays	the	nuances	between	these	two	terms	have	faded	and	
the	 term	metabolic	 profiling	 is	widely	 used.	 Unlike	 genomics,	 transcriptomics	 or	 proteomics	 approaches	 that	
focus	 primarily	 on	 DNA-encoded	 information,	metabolic	 profiling	 provides	 robust	 and	 quantifiable	metabolic	
phenotypes	called	metabotypes	(Gavaghan	et	al.	2000).	Metabotypes	can	be	seen	as	the	intermediary	metabolic	
phenotypes	 existing	 between	 DNA	 variations	 and	 clinical	 disease	 phenotypes	 observed	 in	 animal	 models	 or	
clinical	 samples	 ((Dumas	2012),	 Fig.	1).	Metabolic	profiling	 strategies	deliver	unique	metabolic	 signatures	 that	




used	to	trace	chemical	 imbalances	at	the	brain	 level	 in	the	case	of	CSF,	or	at	the	systemic	 level	 in	the	case	of	
blood	and	urine.	This	is	key	to	identifying	circulating	and	excreted	markers	related	to	CNS	disease	(i.e.	“distant	






In	 this	 review,	 we	 will	 first	 describe	 the	 two	main	 analytical	 techniques	 used	 for	 metabolic	 profiling	 of	 CNS	
conditions:	 proton	 nuclear	magnetic	 resonance	 (1H-NMR)	 spectroscopy	 and	mass	 spectrometry	 (MS).	We	will	
also	discuss	the	importance	of	chemometrics	to	model	metabolic	changes	in	the	brain	and	the	systems	biology	







abundance	 secondary	 metabolites	 remain	 to	 be	 identified	 and	 characterized.	 Several	 metabolites	 are	 of	
particular	pharmacological	relevance	to	study	in	the	context	of	CNS	disorders,	as	up	to	550	metabolites	impact	
human	 pharmacological	 targets	 (Pawson	 et	 al.	 2014).	 Table	 1	 mentions	 metabolites	 that	 behave	 as	
neurotransmitters	or	signaling	molecules	and	their	cognate	receptors	 in	brain.	Most	neurotransmitters	can	be	
quantified	 in	 brain	 tissue	or	 CSF:	 glutamate,	γ-aminobutyric	 acid	 (GABA),	N-acetyl-aspartyl-glutamate	 (NAAG),	
acetylcholine,	 taurine,	 aspartate,	 glycine,	 serotonin,	 dopamine	 as	 well	 as	 their	 precursors:	 acetate,	
choline/phosphatidylcholine,	 glutamine,	 N-acetyl-aspartate	 (NAA),	 tryptophan,	 kynurenines,	 phenylalanine.	
Metabolites	 related	 to	 energy	 metabolism	 are	 also	 quantifiable:	 tricarboxylic	 acid	 (TCA)	 cycle	 intermediates	
(acetate,	 pyruvate,	 citrate,	 α-ketoglutarate),	 glycolysis	 (glucose,	 pyruvate),	 ketone	 bodies	 (acetone,	





lipids	 (e.g.	 glycerol,	 glycerophosphocholine,	 phosphocholine,	 ethanolamine)	 but	 also	 signaling	 lipids	 (e.g.	
ceramides	 and	 sphingosines),	 phosphatidylinositol	 (PI)	 secondary	 messengers,	 G-protein	 coupled	 receptor	







quantified	by	 LC-MS	 (Russell	 et	 al.	 2013).	 The	use	of	 cross-cutting	metabolomics	 technologies	has	 resulted	 in	
several	 studies	 on	 the	 role	 of	 gut	 microbial	 metabolites	 on	 the	 CNS	 and	 initiated	 a	 paradigm	 shift	 in	
neurosciences,	 as	 bacterial	metabolites	 could	 affect	 immunity	 and	behavior	 (Hsiao	 et	 al.	 2013).	 In	 support	 of	
this,	a	study	showed	that	the	neurotransmitter	GABA	can	be	synthesized	by	bacterial	 isolates	from	the	human	
intestine	 (Barrett	 et	 al.	 2012).	 In	 addition,	 microbiota	 appears	 essential	 to	 modulate	 plasmatic	 levels	 of	 the	
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Proton	 nuclear	 magnetic	 resonance	 (NMR)	 spectroscopy	 and	mass	 spectrometry	 (MS)	 are	 the	 key	 analytical	
methods	currently	used	 for	metabolic	profiling	 ((Dunn	et	al.	2011;	Nicholson	et	al.	2002),	Fig.	1).	 1H-NMR	has	
been	predominantly	 used	 for	 CNS	metabolite	 profiling.	However,	NMR	and	MS	detect	 a	 partially	 overlapping	
range	 of	 metabolites	 with	 different	 sensitivity	 and	 sensibility.	 Therefore,	 a	 combined	 platform	 analysis	 is	
recommended	to	increase	metabolic	coverage.	
When	 set	 in	 a	 magnetic	 field,	 the	 nuclei	 of	 a	 molecule	 resonate	 at	 a	 specific	 frequency	 when	 tipped	 by	 a	
radiofrequency	(Beckonert	et	al.	2010;	Beckonert	et	al.	2007).	This	resonance	frequency	is	determined	both	by	
the	magnetic	 field	 intensity	 and	 the	 electronic	 environment	 of	 the	 nuclei	 and	 can	 be	measured	 by	 an	 NMR	
spectrometer.	A	unique	electronic	environment	surrounds	each	atom	of	a	molecule	is	surrounded	by,	therefore,	
each	 recorded	 resonance	 can	 be	 assigned	 to	 a	 specific	 nucleus.	 The	 natural	 abundant	 proton	 (1H)	 is	 the	
preferred	nucleus	for	NMR-based	metabolic	profiling,	although	31P,	13C	and	15N	can	also	be	used.	High	Resolution	
(HR)	 1H-NMR	 provides	 excellent	 spectral	 resolution	 and	 reproducibility	 and	 enables	 detection	 of	metabolites	
above	 the	micromolar	 range.	Owing	 to	 the	 rapidity	of	data	acquisition	 (10	min./sample)	and	 its	 relatively	 low	
cost	 per	 sample,	 1H-NMR	 is	 particularly	 convenient	 for	 high-throughput	 analysis	 of	 liquid	 samples	 (tissue	
extracts,	urine,	plasma,	CSF).	Various	publications	present	standardized	protocols	for	optimal	sampling	and	NMR	
data	 acquisition	 in	 liquid	 phase	 using	 1H-NMR	 (Beckonert	 et	 al.	 2007)	 (Fig.	 1).	 The	 methanol	 chloroform	
extraction	 enables	 the	 simultaneous	 extraction	 of	 both	 lipids	 and	 aqueous	metabolites	 from	a	 single	 sample,	
making	it	well	suited	for	NMR	investigations	of	brain	(Le	Belle	et	al.	2002).	One	advantage	of	NMR	is	that	liquid	
samples	 can	 be	 analyzed	 following	minimal	 sample	 preparation	 limited	 to	 the	 addition	 of	 internal	 standards	
(Beckonert	et	al.	2010;	Beckonert	et	al.	2007):	tetramethylsilane	for	samples	in	organic	solvents	or	trimethylsilyl	
propionate	 for	 aqueous	 samples.	 These	 deuterated	 standards	 are	 used	 for	 calibrating	 the	 chemical	 shifts	
(δ, expressed	in	units	of	parts	per	million,	ppm).	δ	corresponds	to	the	variation	in	resonance	frequency	of	each	
proton	 as	 compared	 to	 the	 standard	 (Fig.	 1).	 The	 development	 of	 magic-angle-spinning	 (MAS)	 1H-NMR	 has	
allowed	 the	 acquisition	 of	 highly	 resolved	 spectra	 directly	 on	 intact	 tissues,	 such	 as	 brain	 tissues	 or	 biopsies	






Over	 the	 last	 decade,	 the	 use	 of	 mass	 spectrometry	 (MS)	 for	 metabolic	 profiling	 has	 been	 impulsed	 by	
improvements	 in	 both	 the	 separation	methods	prior	 to	MS	 analysis	 and	 the	 sensitivity	 of	 detectors.	 Time-of-
flight	and	quadrupole	time-of-flight	(ToF	and	qToF)	detectors	are	now	of	sufficient	sensitivity	to	allow	detection	








acids	 (e.g.	 tryptophan,	 the	 branched	 chain	 amino	 acids:	 valine,	 leucine,	 isoleucine)	 (Dunn	 et	 al.	 2011).	Multi-
dimensional	mass	spectrometry-based	shotgun	lipidomics	(MDMS-SL)	uses	a	targeted	platform	for	specific	study	
of	 lipids	 (Han	 et	 al.	 2011).	 Capillary	 electrophoresis−mass	 spectrometry	 (CE−MS)	 detects	 accurately	 ionic	 and	
highly	polar	metabolites	that	may	not	be	easily	detected	by	either	LC	or	GC-MS	methods	(Ramautar	et	al.	2009).	
Liquid	 chromatography	 coupled	 with	 electrochemical	 colorimetric	 array	 detection	 (LCECA)	 separates	
metabolites	 based	 on	 their	 oxidation	 potential	 and	 was	 used	 to	 detect	 metabolites	 involved	 in	 tryptophan,	
purine	and	tyrosine	pathways	(Bird	et	al.	2012;	Kristal	et	al.	2007).		
After	the	separation	step,	the	sample	is	ionized	and	ions	are	separated	by	the	mass	spectrometer	according	to	







qualitative	 data	 about	 metabolite	 identities.	 There	 is	 however	 a	 bottleneck	 for	 structural	 identification	 in	
untargeted	metabolomics:	metabolites	with	similar	structures	lead	to	signals	overlapping	at	the	same	resonance	
in	 the	NMR	 spectrum,	which	 can	only	be	 resolved	by	using	multidimensional	NMR,	 typically	 1H-1H	and	 1H-13C	














originally	 described	 by	 Pearson	 in	 the	 20’s.	 PCA	 is	 an	 unsupervised	 statistical	 method	 used	 to	 visualize	


















existing	 data	 (R2	 statistic)	 and	 ii)	 predictive	 ability	 for	 new	 data	 (Q2	 statistic,	 root	 mean	 square	 of	 error	 of	
prediction,	RMSEP).	Both	R2	and	Q2	are	 routinely	used	 in	PLS	modeling,	whereas	RMSEP	 tends	 to	be	used	 for	





considering	 that	 a	 model	 with	 a	 Q2Y>0.4	 is	 reliable.	 To	 provide	 more	 systematic	 assessment	 of	 multivariate	
predictive	 significance,	 random	 permutation	 tests	 were	 introduced	 to	 further	 validate	 supervised	 models.	








and	 WT	 mice	 were	 profiled	 using	 HR-MAS	 1H	 NMR	 (Davidovic	 et	 al.	 2011).	 Supervised	 O-PLS-DA	 analyses	
generated	 a	 three-dimensional	 score	 plot	 (Fig.	 2A).	 Each	 position	 on	 the	 plot	 represents	 the	 metabolomic	
fingerprint	derived	from	the	NMR	spectrum	of	an	individual	sample.	We	have	shown	that	control	wild	type	(WT)	
brain	samples	segregate	in	distinct	peripheral	regions	of	the	model.	This	strikingly	illustrates	the	anatomical	and	
functional	 differences	 between	 each	 brain	 region	 that	 is	 directly	 reflected	 in	 their	 distinct	metabolic	 content	
(Fig.	 2A).	 Conversely,	 Fmr1-KO	mouse	 brain	 regions	 all	 tend	 to	 project	 towards	 distinct	 areas	 of	 the	model,	
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indicating	a	characteristic	metabolic	signature	in	KO	samples,	distinct	from	the	WT	samples	(Fig.	2A).	The	O-PLS	
coefficients	 are	 represented	 as	 a	 pseudo-spectrum	 to	 highlight	 the	 spectral	 regions	 directly	 interpretable	 as	










a	 single	metabolite	 is	unlikely	 to	be	a	biomarker	of	a	CNS	disease,	while	 combinations	of	altered	metabolites	
form	 a	 metabolic	 signature	 of	 the	 disease.	 Systems	 biology	 approaches	 were	 introduced	 to	 highlight	 the	
metabolic	pathways	 that	are	significantly	enriched	 in	 the	metabolic	signature	 (Pontoizeau	et	al.	2011;	Xia	and	
Wishart	2010).	 In	metabolite-set	enrichment	analyses	 (MSEA),	 the	complex	metabolic	pattern	 is	mapped	onto	
existing	 metabolic	 pathways	 compiled	 in	 publicly	 available	 databases	 (Figure	 3A).	 For	 example,	 the	 KEGG	
pathway	 database	 is	 widely	 used	 by	 the	 metabolic	 profiling	 community	 and	 integrates	 metabolic,	 genomic,	










Over	 the	 last	 decade,	 there	 has	 been	 a	 marked	 increase	 in	 the	 number	 of	 studies	 characterizing	 the	








Studies	 in	 preclinical	 models.	 Initial	 studies	 using	 metabolic	 profiling	 to	 study	 CNS	 diseases	 examined	 brain	
extracts	from	two	mouse	models	of	Neuronal	Ceroid	Lipofuscinosis	(NCL),	the	most	prevalent	form	of	paediatric	
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neurodegeneration,	 associated	with	 the	CLN3	 (MIM204200)	 and	CLN8	 (MIM	600143)	 loci	 (Griffin	 et	 al.	 2002;	
Pears	et	al.	2005).	Despite	small	samples	size	(n=5),	metabolic	profiling	revealed	that	both	NCL	models	displayed	
converging	metabolic	abnormalities.	These	abnormalities	were	even	detectable	at	one	month	of	age,	before	the	
animals	 expressed	 the	 neurological	 phenotypes	 (Griffin	 et	 al.	 2002;	 Pears	 et	 al.	 2005).	 MSEA	 highlighted	
alterations	 in	 D-glutamate	 and	 D-glutamine	 metabolism	 (Tab.	 3).	 These	 alterations	 were	 in	 agreement	 with	
previously	 reported	changes	 in	expression	of	genes	 involved	 in	glutamine/glutamate/GABA	metabolism	 in	 the	
Cln3	mouse	model	 (Brooks	et	 al.	 2003).	Analysis	 of	 the	plasma	 from	 the	Mdn	model	 reveals	up-regulation	of	
carbonyl	residues,	mainly	lipid	oxidised	species	CH2-CH2-CH2	and	a	decrease	in	lactate	and	glucose,	indicative	of	
increased	oxidative	stress	and	compromised	energetic	metabolism	(Pears	et	al.	2005).	More	recently,	the	mouse	
model	 of	 PHARC	 (polyneuropathy,	 hearing	 loss,	 ataxia,	 retinosis	 pigmentosa,	 and	 cataract)	 disorder	
(MIM612674)	was	studied	using	LC	MS-based	metabolic	profiling	(Blankman	et	al.	2013).	The	disease	is	caused	
by	mutations	 in	 the	 poorly	 characterized	 serine	 hydrolase	 alpha/beta-hydrolase	 domain-containing	 (ABHD)12	





basis	of	human	disorders	 in	mouse	models.	Furthermore,	 these	studies	performed	 in	 rodent	models	strikingly	
highlight	 that	metabolic	abnormalities	are	detectable	even	before	neurological	or	 cognitive	defects	arise,	 and	
across	various	biological	matrices	such	as	brain	tissues	or	biofluids.	
	
Alzheimer’s	 disease	 (AD,	 MIM104300).	 AD	 represents	 the	 most	 common	 form	 of	 progressive	 dementia	
characterized	by	accumulation	of	neurotoxic	plaques	(accumulation	of	abnormally	folded	beta	amyloid	peptide)	








arachidonic	acid	metabolism	were	observed,	 suggestive	of	 the	neuroinflammation	 that	 is	also	observed	 in	AD	
patients	 (Latta	et	al.	2014).	However,	 these	preclinical	 findings	await	 replication	 in	patient	 samples	since	only	
one	 study	 profiled	 the	 metabolome	 of	 post	 mortem	 cortical	 samples	 from	 AD.	 The	 approach	 reached	 94%	
accuracy	for	disease	prediction,	however,	no	metabolite	assignment	was	performed	(Graham	et	al.	2013).		
Studies	 using	 different	 metabolomic	 platforms	 identified	 common	 AD	 markers	 in	 cerebrospinal	 fluid	 from	
patients.	The	metabolism	of	catecholaminergic	neurotransmitters	(dopamine,	epinephrine	and	norepinephrine)	
is	tightly	linked	to	phenylalaline	and	tyrosine	metabolism	and	MSEA	(Tab.	3)	 indicates	convergent	variations	in	
these	 pathways	 (Czech	 et	 al.	 2012).	 Importantly,	 the	 severity	 of	 the	 disease	 was	 correlated	 with	 decreased	
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noradrenaline	 (Kaddurah-Daouk	 et	 al.	 2011b)	 and	 increased	 levels	 of	 vanillylmandelic	 acid,	 a	 degradation	
product	 of	 xanthine	 and	 dopamine	 (Kaddurah-Daouk	 et	 al.	 2013b).	 Also,	MSEA	 (Tab.	 3)	 highlighted	 that	 two	
independent	studies	indicated	alterations	in	methionine	metabolism	(Czech	et	al.	2012;	Ibanez	et	al.	2012).		




of	 cognitively	 normal	 elderly	 adults	 and	 followed	 the	 same	 individuals	 four	 years,	 at	 a	 time	 by	 which	 some	
individuals	 had	 developed	 AD	 (Kanekiyo	 et	 al.	 2014).	 The	 authors	 identified	 a	 metabolic	 signature	 of	 ten	
plasmatic	 lipids	 that	 were	 predictive	 of	 the	 occurrence	 of	 mild	 cognitive	 impairment	 or	 Alzheimer's	 disease	
within	a	2–3	year	timeframe	with	over	90%	accuracy.	These	data	support	the	involvement	of	dyslipidemia	in	AD	




caused	 by	 abnormal	 trinucleotidic	 repeats	 expansions	 in	 the	 Huntingtin1	 (HD1)	 gene	 leading	 to	 motor	
impairment,	 cognitive	 decline	 and	dementia.	HD	 is	 studied	 in	 various	mouse	models	 and	 the	 3-nitropropionic	







systemic	 glucose	 metabolism,	 reflecting	 metabolic	 modifications	 in	 peripheral	 tissues	 in	 addition	 to	 specific	
neurodegenerative	 changes.	 Strikingly,	 similar	 hyperglycemia	 was	 obtained	 when	 comparing	 plasmas	 from	
asymptomatic	 and	 early	 symptomatic	 humans	 and	mice,	 indicating	 a	 clear	 translation	 of	 plasmatic	metabolic	
biomarkers	(Tsang	et	al.	2009;	Tsang	et	al.	2006;	Underwood	et	al.	2006).	An	increased	level	of	glucose	in	plasma	
is	in	line	with	previous	hypothesis	that	HD	is	associated	with	diabetes	(Farrer	1985).	Also,	increased	markers	of	
lipids	 beta-oxidation	 (glycerol	 an	 dethylene	 glycol)	 and	 alterations	 in	 lactate	 levels	 are	 compatible	 with	 a	




neurotransmitters	 and	 BCAA	metabolism	 contribute	 to	 HD	 and	 that	 the	 corresponding	metabolites	 represent	
potential	clinical	biomarkers	that	could	be	useful	to	monitor	disease	progression.	
	
Parkinson’s	 Disease	 (PD,	 MIM168600).	 PD	 is	 the	 second	 most	 common	 neurodegenerative	 disorder	 after	
Alzheimer’s	disease,	 resulting	 from	the	neurodegeneration	of	dopaminergic	neurons	 in	substantia	nigra.	PD	 is	
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associated	 with	 motor	 problems	 (ataxia,	 tremor)	 and	 dementia.	 PD	 is	 mostly	 idiopathic	 but	 can	 also	 be	 of	
genetic	 origin.	 Two	 metabolic	 profiling	 studies	 of	 PD	 patients	 reveal	 decreased	 plasmatic	 levels	 of	 the	
antioxidant	uric	acid,	the	final	product	of	purine	metabolism	(Bogdanov	et	al.	2008;	Johansen	et	al.	2009).	One	
study	showed	that	levels	of	uric	acid	are	negatively	associated	with	PD	and	disease	progression	(Bogdanov	et	al.	
2008;	 Johansen	et	al.	2009).	Also	 levels	of	glutathione	were	 increased	strongly	 reinforcing	 the	contribution	of	
oxidative	 stress	 to	 HD	 (Bogdanov	 et	 al.	 2008;	 Johansen	 et	 al.	 2009).	 Based	 on	 the	 plasmatic	 variations	 of	 9	
metabolites	mostly	involved	in	purine	metabolism,	one	study	could	predict	whether	the	PD	was	secondary	to	a	




Motor	 neuron	 diseases.	Motor	 neuron	 diseases	 form	 a	 heterogeneous	 set	 of	 neurodegenerative	 disorders	
affecting	both	upper	and	 lower	motor	neurons,	which	 trigger	progressive	muscle	atrophy.	The	most	 common	
forms	 of	MND	 are	 amyotrophic	 lateral	 sclerosis	 (ALS,	MIM105400)	 and	 spinocerebellar	 ataxia	 (SCA).	 Various	
brain	 regions	of	 the	mouse	model	 of	 the	motor	 neuron	disease	 Spinocerebellar	Ataxia	 3	 (SCA3,	MIM109150)	
were	 profiled	 (Griffin	 et	 al.	 2004).	 This	 study	 showed	 that	 SCA3	 cerebellum	 is	 the	 most	 affected	 region,	
paralleling	the	strong	cerebellar	deficits	observed	in	SCA3	patients	(Seidel	et	al.	2012).	SCA3	cerebellum	displays	






alterations	 in	pyruvate	and	ketone	body	metabolism	as	revealed	by	MSEA	(Tab.	3).	 Interestingly,	 these	results	









cortex	post	mortem	 samples	 from	bipolar	patients	 reports	 specific	metabolic	changes	associated	with	notable	




lower	 levels	of	 isoleucine	and	glycerol	 in	combination	with	higher	 levels	of	beta-alanine	and	NAA	 (Chen	et	al.	
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2014),	indicative	of	Alanine	metabolism	dysregulations	(Tab.	3).	Metabolic	profiling	of	CSF	samples	reveals	that	





(a	 serotonin	 catabolite)	 and	 4-hydroxy-3-methoxyphenyl	 glycol	 (a	 dopamine	 catabolite)	 are	 correlated	 with	
more	severe	 symptoms	of	anxiety	 (Kaddurah-Daouk	et	al.	2012).	 Systemic	biomarkers	of	depressive	disorders	
were	 identified	 in	 serum	 samples	 from	bipolar	 patients	 (Sussulini	 et	 al.	 2009)	 and	MDD	patients	 (Paige	 et	 al.	
2007).	These	studies	revealed	specific	metabolic	signatures	involving	variations	in	lipids,	neurotransmitters	and	
energy-related	metabolites	(lactate,	acetate	for	BD	and	3-hydroxybutanoic	acid	for	MDD).	Further	studies	using	
bigger	 cohorts	may	contribute	 to	 the	development	of	metabolomics-based	biomarkers	 for	 future	diagnosis	of	
various	forms	of	depressive	disorders.	
	
Schizophrenia	 (SCZ,	MIM181500).	SCZ	 is	 a	 common	disorder	with	a	 lifetime	prevalence	of	approximately	1%.	








and	 acetate	 (Holmes	 et	 al.	 2006).	 To	 further	 substantiate	 the	 relevance	of	 studying	CSF	metabolic	 profiles	 to	
predict	disease,	metabolic	profiling	of	patients	prodromal	for	psychosis	-which	is	usually	considered	as	the	early	
clinical	 stage	 prior	 to	 onset	 of	 psychosis	 and	 schizophrenia-	 showed	 that	 36%	 of	 these	 patients	 displayed	
metabolic	 profiles	 characteristic	 of	 schizophrenia	 patients	 (Huang	 et	 al.	 2007).	 This	 suggests	 that	 detectable	
metabolic	 alterations	 precede	 the	 occurrence	 of	 overt	 psychosis,	 making	 it	 possible	 to	 identify	 prodromal	
markers.	
Systemic	 markers	 were	 identified	 in	 the	 plasma	 of	 drug-naive	 SCZ	 patients,	 highlighting	 a	 decrease	 in	
polyunsaturated	fatty	acids	PUFAs	(n3,	n6	and	n9	fatty	acid	families),	in	energy	substrates	(lactate,	acetoacetate,	
glucose)	and	uric	 acid	 (Cai	et	 al.	 2012).	 This	hypo-uremia	was	also	detected	 in	 the	plasma	of	an	 independent	
cohort	 of	 SCZ	 patients	 (Yao	 et	 al.	 2010a;	 Yao	 et	 al.	 2010b).	 Uric	 acid	 being	 the	 main	 plasmatic	 antioxidant,	
decreased	 levels	 in	 biofluids	 of	 SCZ	 patients	 is	 indicative	 of	 increased	 susceptibility	 to	 oxidative	 stress,	
corroborating	several	studies	in	animal	models	and	patients	(Emiliani	et	al.	2014).	Finally,	several	gut	microbial	
metabolites	such	as	hippurate	and	trimethylamine	presented	altered	levels	in	the	urine	of	SCZ	patients	(Cai	et	al.	







al.	 2006;	 Huang	 et	 al.	 2007)	 of	 SCZ	 patients	 (Tab.	 2).	 Metabolic	 profiling	 of	 SCZ	 patients	 before	 and	 after	
antipsychotic	treatment	was	performed	in	brain	samples,	CSF	and	plasma.	Metabolic	markers	were	identified	in	
post	mortem	brain	 tissue	 from	drug-naïve	 schizophrenic	patients,	 corresponding	 to	amino	acid	and	glutamine	
metabolism	normalized	by	 lifetime	antipsychotic	 treatment	 (Chan	et	al.	2011).	One	of	 the	key	 findings	 is	 that	
patients	responding	to	atypical	antipsychotics	(50%	of	patients)	present	a	normalization	of	their	CSF	metabolic	
profiles	well	before	clinical	improvements	were	observed	(Chan	et	al.	2011;	Holmes	et	al.	2006). Conversely,	no	
normalization	 of	 the	 CSF	 metabolic	 signature	 was	 observed	 in	 patients	 in	 whom	 treatment	 had	 not	 been	
initiated	 at	 the	 first	 psychotic	 episode	 (Holmes	 et	 al.	 2006).	 This	 study	 highlights	 at	 the	metabolic	 level	 the	
importance	 of	 early	 therapeutic	 intervention	 for	 schizophrenic	 patients.	 In	 two	 independent	 studies	 using	
different	 metabolomics	 platforms	 plasmatic	 metabolic	 signature	 of	 schizophrenia	 was	 normalized	 upon	
treatment	with	the	antipsychotic	risperidone	(Cai	et	al.	2012;	Yao	et	al.	2010a).	One	study	studied	in	details	the	
plasmatic	lipidic	profiles	of	SCZ	patients	before	and	after	3	weeks	treatment	with	the	antipsychotics	olanzapine,	








Autism	 spectrum	 disorders	 (ASD,	 MIM209850).	 ASD	 constitute	 a	 family	 of	 complex	 neurodevelopmental	
disorders.	ASD	patients	display	 impairments	 in	social	 interactions	and	communication,	 restricted	 interests	and	
increased	 anxiety.	 ASD	 originates	 from	 a	 combination	 of	 genetic	 and	 environmental	 factors.	 Notably,	 strong	
correlations	between	maternal	 infection	during	pregnancy	and	ASD	incidence	have	been	described	(Knuesel	et	
al.	2014).	The	maternal	immune	activation	(MIA)	mouse	model	of	environmentally-triggered	ASD	is	obtained	by	







how	 metabolic	 profiling	 contributes	 to	 elucidate	 the	 molecular	 trigger	 of	 altered	 behavior	 in	 MIA	 ASD	 and	
strengthen	the	link	between	altered	microbiota	and	ASD.	
This	link	is	also	supported	by	the	identification	of	several	altered	urinary	metabolites	of	microbial	origin	in	ASD	
patients.	 Notably,	 variations	 in	 the	 microbial-mammalian	 co-metabolites:	 dimethylamine,	 hippurate	 and	
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phenylacetylglutamine	were	observed	in	one	cohort	of	ASD	patients	(Yap	et	al.	2010).	Variations	in	the	urinary	
levels	of	microbial-mammalian	 co-metabolites	were	also	 identified	 in	an	 independent	 cohort	of	ASD	patients:	
hippurate,	 one	 of	 its	 precursors	 3-hydroxyphenylacetate	 and	 co-metabolite	 3-hydroxyhippurate,	 as	 well	 as	
indole-3-acetate	 (Emond	 et	 al.	 2013).	 These	 studies	 performed	 in	 ASD	 mouse	 models	 and	 clinical	 samples	




triplication	 of	 chromosome	 21.	 Serum	metabolic	 profiling	 of	 first-trimester	 pregnant	women	 identified	 novel	














most	 frequent	 identified	 genetic	 cause	 for	 autism-spectrum	disorders	 since	 15-20%	of	 FXS	 patients	meet	 the	
criteria	for	ASD	(Penagarikano	et	al.	2007).	A	comprehensive	metabolomic	study	on	various	brain	regions	of	the	
FXS	 mouse	 model,	 the	 Fmr1-knockout	 mouse	 (Mientjes	 et	 al.	 2006),	 has	 revealed	 region-specific	 metabolic	
signature,	 with	 cerebellum	 and	 cortex	 being	 the	 most	 affected	 regions	 (Davidovic	 et	 al.	 2011).	 This	 study	
indicated	 that	 various	 neurotransmitters,	 including	 GABA,	 glutamate,	 taurine	 and	 acetylcholine	 and	 their	









metabolic	 signatures	associated	 to	 the	above-mentioned	disorders	and	converge	 towards	 the	 identification	of	
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glutamate	 (Moffett	 et	 al.	 2007)	 and	 its	 levels	 are	 decreased	 in	 a	 number	of	 CNS	 conditions	 (Tab.2).	NAA	 is	 a	
neuronal	 osmolyte,	 as	 well	 as	 a	 precursor	 for	 both	 lipid	 and	 myelin	 synthesis	 in	 oligodendrocytes	 and	 a	
precursor	 of	 the	 neurotransmitter	 N-acetylaspartylglutamate	 (NAAG).	 MSEA	 of	 the	 metabolic	 signatures	
determined	 in	 various	 neurological	 conditions	 (Tab.	 3)	 reveals	 terms	 linked	 to	 biosynthesis	 of	 amino-acid	





Lactate	 is	 normally	 a	 breakdown	 product	 of	 glycolysis,	 however,	 several	 studies	 now	 suggest	 that	 lactate	 is	
metabolized	by	the	intact	brain	in	an	activity-dependent	manner	and	has	a	direct	neuroprotective	effect	(Wyss	
et	al.	2011).	MSEA	of	CSF	metabolic	signatures	of	ALS	and	schizophrenia	present	the	terms	“Gluconeogenesis”	or	
“Pyruvate	metabolism”	 (Tab.	 3).	 Brain	 energy	 supply	 is	 required	not	only	 for	 basal	 cellular	metabolism	which	
results	 in	 ATP	 fuelling	 for	 basic	 biological	 reactions,	 but	 also	 for	 the	 synthesis	 and	 degradation	 of	
neurotransmitters,	 preservation	 of	 membrane	 ionic	 gradients	 and	 maintenance	 of	 secondary	 messengers	




partially	overlap	 (Tab.	2),	 relying	on	a	 single	biomarker	 to	predict	a	 specific	CNS	disease	 is	not	 sufficient.	One	
may	more	rely	on	combinations	of	biomarkers,	which	may	define	altered	metabolic	pathways	and	will	be	more	
precise	 than	a	single	biomarker	 to	detect	and	monitor	 the	disease.	Metabolomic	models	 for	prediction	of	 the	
diseases	 are	 built	 on	 several	 metabolites,	 illustrating	 the	 necessity	 to	 use	 global	 metabolic	 signatures	 that	
guarantee	the	specificity	of	the	diagnosis.	Importantly,	systemic	biomarkers	detectable	in	urine,	plasma	or	CSF	
would	 be	 the	most	 relevant	 for	 translation	 to	 human	 and	 several	 studies	 demonstrate	 the	 great	 potential	 of	
















Cell	 type	 and	 organelle-specific	 metabolomics.	 So	 far,	 metabolic	 profiling	 studies	 have	 focused	 on	 global	
changes	 in	CNS-specific	metabolites	 (brain,	 CSF)	 or	 systemic	markers	 (plasma,	 urine)	 to	predict	 diseases.	One	
current	 challenge	 in	 the	 metabolomics	 field	 would	 be	 to	 move	 to	 the	 study	 of	 cell-type	 specific	 metabolic	
variations.	For	example,	primary	cultures	of	neurons	or	astrocytes	of	animal	models	of	CNS	diseases	could	be	
used	 to	 detect	 cell-type	 specific	 metabolic	 variations	 which	 could	 help	 determine	 whether	 the	 global	 brain	
changes	originate	more	from	one	cell	type	or	another	and	help	refine	more	targeted	treatments.	A	recent	study	
combined	whole-cell	 patch	 clamp	 recording	 and	 capillary	 electrophoresis	 (CE)-mass	 spectrometry	 (MS)-based	
metabolomics	to	gather	information	at	the	single-cell	level	on	ex	vivo	rat	brain	thalamic	slices	(Aerts	et	al.	2014).	
Patch-clamp	recording	yielded	information	on	the	electrophysiological	properties	of	the	selected	cell.	The	patch-
clamp	pipette	was	 then	used	 to	 retrieve	a	portion	of	 the	cytoplasm	of	 the	 recorded	cells,	providing	sufficient	
substrate	 for	 metabolomic	 analysis	 using	 CE-MS.	 Combining	 morphological,	 electrophysiological	 data	 and	
neurochemical	of	each	recorded	cell	profile	enabled	to	accurately	determine	their	very	nature:	glutamatergic	or	
GABAergic	inhibitory	neurons	or	astrocytes.	This	study	shows	that	adjacent	thalamic	nuclei	produce	dramatically	
different	neurotransmitter	 profiles,	 reflecting	 their	 unique	neuronal	 populations.	 The	 current	development	of	
induced	pluripotent	 cells	 (iPS	 cells)	 from	CNS	disease-affected	patient’s	 fibroblasts,	 that	have	 the	 capacity	 for	
differentiation	 into	specific	neuronal	or	glial	 lineages	offers	great	promises	 in	 the	 field	 (Orlacchio	et	al.	2010).	
Such	 approach	 would	 also	 provide	 insights	 in	 the	 neuron/glial	 cell	 co-metabolome.	 Importantly,	 the	
development	 of	 high-throughput	 methodologies	 for	 metabolomic	 analysis	 would	 enable	 systematic	 drug	
screening	on	neuronal	or	glial	cultures	systems,	as	performed	on	cancer	cell	lines	and	primary	cultures	(Tiziani	et	
al.	2011).	In	addition,	metabolic	profiling	will	provide	information	on	cell-specific	secondary	effects	of	drugs	and	
help	 refine	 treatments.	Another	 challenge	 lies	 in	 the	metabolic	 profiling	of	 smaller	 cellular	 compartments	 via	
organelle	 metabolomics.	 Nerve	 terminals	 preparations	 such	 as	 synaptoneurosomes	 could	 be	 analyzed	 to	
determine	the	specific	 levels	of	neurotransmitters	 in	these	structures	 in	CNS	pathological	conditions.	Also,	the	
study	 of	membrane-enriched	 preparation	 could	 lead	 to	 the	 accurate	 determination	 of	 the	 lipids	 composition	
with	different	electrical	properties.		
	
Pharmacometabonomics.	 	 Another	 key	 perspective	 has	 been	 introduced	with	 the	 accurate	 prediction	 of	 the	





of	Major	 Depressive	 Depression	 (MDD)	 (Kaddurah-Daouk	 et	 al.	 2013a;	 Kaddurah-Daouk	 et	 al.	 2011a).	 In	 the	
latest	double-blind	pharmacometabolomic	study	(Kaddurah-Daouk	et	al.	2013a),	the	authors	tested	whether	the	
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baseline	 metabolic	 profile	 of	 a	 patient	 with	 MDD	 can	 predict	 patient	 response	 to	 treatment	 with	 the	




et	 al.	 demonstrated	 that	 mutations	 in	 branched	 chain	 amino	 acid	 keto	 dehydrogenase	 kinase	 gene	 (BCKDK)	
were	 associated	with	 a	 particular	 form	 of	 heritable	 autism	with	 epilepsy	 (Novarino	 et	 al.	 2012).	 These	 three	
studies	suggest	that	BCAAs	(and	potentially	other	metabolites)	play	a	prominent	role	in	CNS	disorders	and	that	





into	 responding	 and	 non-responding	 groups	 to	 determine	 the	 best	 treatment	 based	 on	 predose	 metabolic	




of	 genetic	 determinants	 for	metabolic	 phenotypes	 (i.e.,	 metabotypes).	 By	 acquiring	 genome-wide	 genotyping	
and	metabolic	phenotyping	data	in	parallel,	 it	 is	now	possible	to	determine	quantitative	trait	 loci	for	metabolic	
traits	 (mQTL,	 i.e.	 polymorphisms	 determining	 metabolite	 abundance)	 in	 genetic	 intercrosses	 in	 rodents	 or	
segregating	 human	 populations	 (Dumas	 et	 al.	 2007;	 Suhre	 et	 al.	 2011a;	 Suhre	 et	 al.	 2011b).	 Using	 a	 similar	
approach,	brain	metabolic	profiles	could	be	correlated	to	DNA	polymorphisms	and	haplotypes	to	identify	brain-
specific	mQTLs,	which	should	result	in	a	better	understanding	of	the	genetic	regulation	of	brain	metabotypes;	at	
least	 in	 animal	 models.	 The	 affordability	 of	 next	 generation	 sequencing	 methods	 in	 combination	 with	
corresponding	metabolomic	data,	would	enable	 in	the	near	future	mQTL	applications	to	highlight	susceptibility	
SNPs	and	CNVs	for	neurological	diseases	of	complex	etiology,	such	as	schizophrenia,	bipolar	disorder	or	autism-
spectrum	disorders.	 An	 integrated	metabolomic	 and	 genomic	 approach	was	 used	 to	 study	 selective	 serotonin	
reuptake	inhibitor	(SRI)	treatment	outcome	in	patients	with	major	depressive	disorder	(MDD)	(Ji	et	al.	2011).	This	
study	 shows	 that	 glycine	 levels	 are	 negatively	 correlated	 to	 SRI	 treatment	 outcome,	 indicating	 that	 discrete	




(Ji	et	al.	2012).	These	two	studies	 illustrate	 that	GWAS	 identify	SNPs	and	candidate	genes	validating	metabolic	





Integration	 of	 biological	 and	 signalling	 networks	 regulating	 brain	 metabotypes.	Metabolite-set	 enrichment	
analysis	 algorithms	 represent	 a	 real	 progress	 in	 terms	 of	 unbiased	 assessment	 of	 the	 coherence	 of	metabolic	
signatures	 at	 the	 pathway	 level,	 which	 is	 not	 always	 the	 case,	 as	 exemplified	 in	 Tab.	 2	 presenting	metabolic	
signatures,	which	do	not	yield	significant	enrichment	in	metabolic	pathways	(Tab.	3).	MSEA	approaches	remain	
limited	 because	 (i)	 they	 test	 metabolite	 for	 membership	 in	 metabolic	 pathways	 using	 arbitrary	 pathway	
definitions.	(ii)	they	do	not	provide	any	understanding	of	the	regulation	of	metabolic	patterns,	for	instance	how	
disease	 causing	 genes	 (if	 known)	mechanistically	 contribute	 to	 the	 observed	metabolic	 signature.	 In	 order	 to	
address	 these	 challenges,	 we	 used	 interactome-based	 systems	 biology	 strategies,	 by	 coupling	 protein-protein	
interaction	networks	and	signaling/transduction	pathways	to	metabolic	pathways	(Davidovic	et	al.	2011).	A	novel	
alternative	 strategy,	 integrated	metabolome	and	 interactome	mapping”	 (iMIM)	was	devised	and	 implemented	
(Figure	 3A).	 Using	 iMIM,	 metabolic	 phenotypes	 are	 directly	 mapped	 onto	 a	 compilation	 of	 protein-protein	
interaction	 (ppi),	 metabolite-enzyme	 interactions	 and	 ligand-receptor	 interactions	 networks	 extracted	 from	
literature	and	databases.	Since	the	human	interactome	is	estimated	to	have	650,000	ppi	(Stumpf	et	al.	2008),	the	





These	 central	 proteins	 correspond	 to	 key	 regulators	 relaying	 the	 signal	 between	 the	 causal	 genes	 and	 the	
metabolites.	Using	iMIM	approach,	we	identified	the	regulatory	proteins	controlling	the	metabolic	signature	of	
Fragile	X	Syndrome	in	the	brain,	and	identified	links	with	Alzheimer’s	disease	and	oxidative	stress	(Davidovic	et	









The	 study	 of	 brain	 metabolism	 and	 CNS	 diseases	 has	 recently	 witnessed	 a	 series	 of	 shifts,	 related	 to	 the	






metabolic	 biochemistry	 will	 undoubtedly	 lead	 to	 a	 better	 understanding	 of	 CNS	 disease	 mechanism.	 The	
translation	 of	 pharmacometabonomic	 approaches	 identifying	 predictive	 circulating	 markers	 for	 treatment	
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1,000	 individuals),	 whereas	 for	 animal	 models	 n=5-10	 per	 condition	 should	 be	 sufficient.	 B.	 Biofluids	 (urine,	
plasma,	CSF,	 saliva)	or	 intact	brain	 samples	or	extracts	are	 collected	 in	a	 standardized	manner	 (biopsies,	post	
mortem	 samples,	 surgery	 resection).	 C.	 Spectral	 data	 are	 acquired	 on	 each	 sample	 using	 Nuclear	 Magnetic	
Resonance	or	Mass	 Spectrometry,	 followed	by	 computer-assisted	data	 import,	 preprocessing	 and	databasing,	
resulting	 in	 a	 megavariate	 matrix	 summarizing	 the	 metabolite	 peaks	 (variables,	 1	 to	 k)	 for	 each	 sample	
(individuals,	 1	 to	 n).	D.	 Extensive	 pattern	 recognition	multivariate	 statistical	 analysis	 of	 spectral	 data	 enables	
classification	and/or	prediction	of	diseased	and	control	samples	based	on	statistical	scores	 (left	graph).	Model	
loadings	 are	 derived	 to	 determine	 the	 metabolites	 whose	 variations	 maximize	 the	 discrimination	 between	
diseased	and	healthy	individuals.	Orthogonal	Partial	Least	Square	Discriminant	Analysis	(O-PLS-DA)	models	can	
be	represented	as	a	pseudo-spectrum	(right	graph).	Correlation	to	the	class	of	the	sample	(diseased	or	healthy)	
is	 given	 by	 color-scaled	 covariance	 values.	 Positive	 model	 coefficients	 correspond	 to	 higher	 metabolite	
concentrations	 in	 the	 diseased	 condition,	 whereas	 negative	 model	 coefficients	 are	 associated	 with	 higher	
metabolite	 concentrations	 in	 healthy	 condition.	 Significantly	 affected	 metabolites	 represent	 candidate	
biomarkers	of	the	disease,	here	m1	to	m3.	
	
Figure	 2.	Metabolomics	 in	 CNS	 research	 by	 example:	 the	metabolic	 signature	 of	 Fragile	 X	 Syndrome	 in	 the	
brain	of	its	mouse	model.		
A.	 Following	 initial	 metabolic	 profiling	 of	 four	 brain	 anatomical	 regions	 (cortex,	 cerebellum,	 striatum	 and	
hippocampus)	by	1H	HR-MAS	NMR	spectroscopy,	the	metabolic	variation	related	to	brain	region	and	FXS	disease	
status	 was	 analysed	 using	 orthogonal	 partial	 least	 square	 discriminant	 analysis.	 The	 3D	 O-PLS-DA	 score	 plot	
shows	an	efficient	 segregation	of	 the	eight	 groups	of	 brain	 samples,	 based	on	anatomical	 region	and	disease	
status.	B.	To	highlight	the	metabolites	responsible	for	the	FXS	signature	in	cortical	samples,	the	O-PLS-DA	model	
loadings	 were	 represented	 as	 a	 pseudo-spectrum	 plot.	 Positive	 model	 coefficients	 correspond	 to	 higher	





metabolic	 pattern,	 which	 can	 be	 difficult	 to	 interpret.	 Using	 previous	 knowledge	 about	 metabolic	 pathways	
compiled	 in	 a	 database,	 the	 complex	 metabolic	 pattern	 is	 then	 mapped	 onto	 the	 metabolic	 pathways.	 The	
metabolic	 pattern	 is	 repeatedly	 tested	 for	 association	with	 each	 pathway	 in	 the	 database,	 using	 enrichment	
tests	 such	as	Χ2	 test	 in	 the	 case	of	a	qualitative	overrepresentation	analysis,	or	 for	a	quantitative	enrichment	
analysis	 (Pontoizeau	 et	 al.	 2011;	 Xia	 and	 Wishart	 2010).	 The	 result	 of	 the	 analysis	 if	 finally	 displayed	 in	 a	
summary	 plot,	 as	 obtained	 using	 free	 online	 resources	 such	 as	 the	MSEA	webserver	 (www.msea.ca,	 (Xia	 and	
Wishart	 2010)).	B.	 Integrated	Metabolome	and	 Interactome	Mapping. :	 a	 strategy	 to	 navigate	 the	underlying	
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signalling	networks	and	understand	metabolic	signatures.	Disease-causing	candidate	genes	are	put	into	relation	
with	 patterns	 of	 significant	 metabolites	 via	 protein-protein	 and	 metabolite-protein	 interactions.	 The	 iMIM	





edges.	 In	 iMIM,	 network	 metrics	 are	 then	 used	 to	 define	 shortest	 paths	 and	 pivotal	 proteins	 between	
metabolites	and	disease-causing	genes. One	strategy	to	efficiently	rank	these	proteins	is	to	use	the	betweenness	





Table	 1.	 Examples	 of	 pharmacologically	 active	metabolites	 and	 their	 cognate	 receptors	 of	 relevance	 in	 CNS	
disorders.		
Each	 metabolite	 is	 provided	 with	 database	 identifiers	 to	 enable	 direct	 consultation	 of	 several	 metabolic	
databases:	 KEGG	 (http://www.genome.jp/kegg/compound/),	 Human	 Metabolome	 Database	 (HMDB:	
http://www.hmdb.ca/)	or	PubChem	(http://pubchem.ncbi.nlm.nih.gov/)	to	retrieve	information	on	structure	or	
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Metabolite KEGG	  ID HMDB	  ID PubChem	  ID Receptor	  official	  human	  gene	  symbol Receptor	  class
Neurotransmitters 5-­‐Hydroxytryptamine	   C00780 HMDB00259 5202 HTR1A/B/D/E/F,	  HTR2A/B/C,	  HTR3A/B/C/D/E,	  HTR4,	  HTR5A,	  HTR6,	  HTR7 5-­‐Hydroxytryptamine	  receptors
Acetylcholine C01996 HMDB00895 187 CHRM1,	  CHRM2,	  CHRM3,	  CHRM4,	  CHRM5,	   Acetylcholine	  receptors,	  Muscarinic
CHRNA1/2/3/4/5/6/7/9/10,	  CHRNB1/2/3/4,	  CHRND,	  CHRNE,	  CHRNG Acetylcholine	  receptors,	  Nicotinic
Adenosine C00212 HMDB00050 60961 ADORA1,	  ADORA2A/B,	  ADORA3 Adenosine	  receptors
Adrenaline C00788 HMDB00068 5816 ADRA1A/B/D,	  ADRA2A/B/C,	  ADRB1/2/3 Adrenergic	  receptors
Noradrenaline C00547 HMDB00216 439260
Dopamine C03758 HMDB00073 681 DRD1/2/3/4/5 Dopamine	  receptors
GABA C00334 HMDB00112 119 GABRA1/2/3/4/5/6,	  GABRB1/2/3,	  GABRG1/2/3,	  GABRD,	  GABRE,	  	  GABRQ GABAA	  receptors
GABBR1/2 GABAB	  receptors
GABRR1/2/3 GABAC	  receptors
Glutamate C00217 HMDB03339 23327 GRIA1/2/3/4,	  GRIK1/2/3/4/5,	  GRIN1/2A/2B/2C/2D/3A/3B Glutamate	  receptors,	  Ionotropic
GRM1/2/3/4/5/6/7/8 Glutamate	  receptors,	  Metabotropic
Glycine	   C00037 HMDB00123 750 GLRA1/2/3/4,	  GLRB Glycine	  receptors
Melatonin C01598 HMDB01389 896 MTNR1A/AB Melatonin	  receptors
Phosphates ATP C00002 HMDB00538 5957 P2RX1/2/3/4/5/6/7 P2X	  receptors,	  transmitter-­‐gated	  channels
ADP C00008 HMDB01341 6022 P2YR1/12/13 P2Y	  receptors,	  G-­‐protein-­‐coupled
ATP C00002 HMDB00538 5957 P2RY2/11
UDP C00015 HMDB00295 6031 P2RY6
UTP C00075 HMDB00285 6133 P2RY2/4
UDP-­‐glucose C00029 HMDB00286 53477679 P2RY14
Inositol	  triphosphate C00081 HMDB00189 8583 ITPR1/2/3 Inositol	  triphosphate	  receptors
Lipids Leukotriene	  B4 C02165 HMDB01085 5280492 LTB4R1/R2 Leukotriene	  receptors
Lysophosphatidic	  acid C00681 HMDB07853 3950 LPR1/2/3/4/5/6 Lysophospholipid	  receptors
Sphingosine-­‐1-­‐phosphate C06124 HMDB00277 5353956 S1PR1/2/3/4/5
Leukotriene	  B4 C02165 HMDB01085 5280492 PPARA Peroxisome	  proliferator	  activated	  receptor	  α
5-­‐Hydroxyeicosatetraenoic	  acid C04805 HMDB11134 5280733
Unsaturated	  fatty	  acids FA0103 N/A N/A
Prostaglandin	  I2 C01312 HMDB01335 5282411 PPARD Peroxisome	  proliferator	  activated	  receptor	  δ
Unsaturated	  fatty	  acids FA0103 N/A N/A
5-­‐Hydroxyeicosatetraenoic	  acid C04805 HMDB11134 5280733 PPARG Peroxisome	  proliferator	  activated	  receptor γ
9-­‐Hydroxyoctadecadienoic	  acid C14767 HMDB10223 5282945
13-­‐Hydroxyoctadecadienoic	  acid C14762 HMDB06939 6443013
Prostaglandin	  J2 C05957 HMDB02710 5280884
Prostaglandin	  D C00925 HMDB00693 53477714 PTGDR/DR2 Prostanoid	  receptors
Prostaglandin	  E C00584 HMDB01220 5280360 PTGER1/ER2/ER3/ER4
Prostaglandin	  F1 C05442 HMDB00937 5280794 PTGFR
Arachidonoylethanolamine C10203 HMDB32696 5281706 CNR1/2 Cannabinoid	  receptors
2-­‐Arachidonoylglycerol C10521 HMDB34127 5281804
Disease Samples	  details	   Reference Number	  of	  samples Analytical	  platform Metabolites
NEURODEGENERATIVE	  
DISORDERS
Mdn	  mouse	  model	   Griffin	  et	  al.	  2002 brain/plasma n=5	  per	  group HR	  1H-­‐NMR Brain	  UP:	  beta-­‐hydroxybutyrate,	  taurine,	  glutamate,	  CH2CH2CH2	  lipids	  DOWN:	  
creatine,	  glutamine,	  gamma-­‐aminobutyric	  acid	  Plasma	  UP:	  CH2CH2CH2	  lipids	  DOWN:	  
lactate,	  CH3-­‐CH2	  lipids,	  glucose
Cln3	  mouse	  model Pears	  et	  al.,	  2005 brain n=5	  per	  group HR	  1H-­‐NMR UP:	  glutamate,	  myo-­‐inositol,	  creatine	  	  DOWN:	  gamma-­‐aminobutyric	  acid,	  lactate,	  
taurine,	  N-­‐acetyl-­‐aspartate	  
Cln3	  mouse	  model	  brain Griffin	  et	  al.,	  2005 brain n=5	  per	  group HR	  1H-­‐NMR UP:	  glutamate,	  myo-­‐inositol,	  creatine	  	  DOWN:	  gamma-­‐aminobutyric	  acid,	  lactate,	  
taurine,	  N-­‐acetyl-­‐aspartate	  
PHARC Abhd12	  mouse	  model Blankman	  et	  al.,	  2013 brain n=3-­‐5	  per	  group LC	  MS phosphatidylserine	  (2	  sp.	  up;	  2	  sp.	  down),	  lysophosphatidylserine	  (7	  sp.	  up),	  
phosphatidylglycerol	  (2	  sp.	  up;	  1	  sp.	  down),	  	  lysophosphatidylinositol	  (1	  sp.	  up;	  1	  sp.	  
down)
CRND8	  mouse	  model	   Lin	  et	  al.,	  2013 brain n=6	  per	  group LC-­‐MS hippurate,	  salicylurate,	  prostaglandin	  E1/E3/B1/H2/FF2beta/A2/F1alpha	  and	  
derivatives,	  16-­‐hydroxy-­‐2,12-­‐dimethoxypicrasa-­‐2,12-­‐diene-­‐1,11-­‐dione,	  5-­‐
hydroxyeicosatetraenoic	  acid,	  leukotriene	  A4,	  6-­‐phospho-­‐D-­‐gluconate,	  9-­‐oxononanoic	  
acid,	  androsterone,	  glucuronide,	  mannitol,	  11beta-­‐17-­‐Dihydroxy-­‐6alpha-­‐methylpregn-­‐
4-­‐ene-­‐3,20-­‐dione,	  dehydrovomifoliol,	  D-­‐glucuronate,	  oleandolide,15S-­‐hydroxy-­‐11-­‐oxo-­‐
5Z,9Z,13E,17Z-­‐prostatetraenoic	  acid,	  annabidiolic	  acid,	  4-­‐heptyloxybenzoic	  acid,	  5-­‐
oxo-­‐1,2-­‐campholide
Tg2576	  mouse	  model Lalande	  et	  al.,	  2014 brain n=5	  per	  group HR	  1H-­‐NMR DOWN:	  glutamate,	  	  N-­‐acetylaspartate,	  myo-­‐inositol,	  creatine,	  gamma-­‐aminobutyric	  
acid,	  phosphocholine	  
human	  post	  mortem	   Graham	  et	  al.,	  2013 brain n=15	  controls	  n=15	  patients UPLC-­‐QTOF-­‐MS Unassigned	  metabolites
human	  post	  mortem	   Kaddurah-­‐Daouk	  et	  al.	  2011 CSF n=15	  controls	  n=15	  patients LCECA	  HPLC UP:	  5-­‐hydroxytryptophan,	  methoxy-­‐hydroxyphenyl-­‐glycol,	  methoxy-­‐
hydroxymandelate	  	  	  	  	  DOWN:	  norepinephrine,	  3-­‐methoxytyramine,	  alpha	  tocopherol,	  
ascorbate	  
human Kaddurah-­‐Daouk	  et	  al.,	  2013 CSF n=38	  controls	  n=40	  patients LCECA	  HPLC UP:	  methionine,	  5-­‐hydroxyindoleacetic	  acid,	  vanillylmandelic	  acid,	  xanthosine,	  
gluthatione	  	  DOWN:	  gluthatione/methionine,	  	  5-­‐hydroxyindoleacetic	  acid/5-­‐
hydroxytryptophan
human Ibanez	  et	  al.	  2012 CSF n=85	  patients CE-­‐MS UP:	  choline,	  valine,	  serine	  	  	  DOWN:	  carnitine
human Czech	  et	  al.,	  2012 CSF n=51	  controls	  n=79	  patients GC-­‐MS	  LC-­‐MS/MS cysteine,	  tyrosine,	  phenylalanine,	  methionine,	  serine,	  pyruvate,	  taurine,	  creatinine,	  
cortisol,	  dopamine,	  uridine
human Oresic	  et	  al.,	  2011 plasma n=46	  controls	  n=47	  patients UPLC-­‐MS/GCxGC-­‐MS DOWN:	  ether	  phospholipids,	  phosphatidylcholines,	  sphingomyelins,	  sterols
human Han	  et	  al.,	  2011 plasma n=26	  controls	  n=26	  patients MDMS-­‐SL UP:	  ceramide	  (65	  sp.)	  DOWN:	  sphingomyelin	  (33	  sp.)
human Mapstone	  et	  al.,	  2014 plasma n=525	  participants MDMS-­‐SL serotonin,	  phenylalanine,	  proline,	  lysine,	  phosphatidylcholine	  (10	  sp.),	  taurine,	  
acylcarnitine	  
R6/2	  mouse	  model Tsang	  et	  al.	  2006b brain/plasma/urine n=10	  per	  group HR/HR-­‐MAS	  1H-­‐NMR	   Brain	  UP:	  creatine,	  glutamine,	  lactate	  DOWN:	  acetate,	  N-­‐acetyl-­‐aspartate,	  gamma-­‐
aminobutyric	  acid,	  choline	  Plasma	  UP:	  glucose,	  unsaturated	  lipids,	  creatine	  DOWN:	  
glutamate	  Urine	  UP:	  glucose,	  acetate,	  citrate,	  glycine,	  2-­‐oxoglutarate,	  succinate	  
trimethylamine	  N	  oxide	  DOWN:	  alpha-­‐ketoisocaproate,	  dimethylglycine,	  lactate,	  
spermine,	  trimethylamine
3-­‐Nitropropionic	  acid	  rat	  model Tsang	  et	  al.	  2009 brain n=5	  per	  group HR-­‐MAS	  1H-­‐NMR UP:	  succinate	  	  DOWN:	  taurine,	  gamma-­‐aminobutyric	  acid,	  creatine,	  N-­‐acetyl-­‐
aspartate,	  choline
HD-­‐N171-­‐N82Q	  mouse Underwood	  et	  al.,	  	  2005 plasma n=10	  per	  group GC-­‐TOF-­‐MS glycerol,	  glucose,	  monosaccharides,	  lactate,	  urea,	  malonate,	  valine,	  pyroglutamate
human Underwood	  et	  al.,	  	  2005 plasma n=20	  controls	  n=30	  patients GC-­‐TOF-­‐MS glycerol,	  monosaccharides,	  lactate,	  alanine,	  leucine,	  2-­‐amino-­‐N-­‐butyrate,	  ethylene	  
glycol,	  alpha-­‐hydroxybutyric	  acid,	  valine,	  malonate,	  urea
human	   Mochel	  et	  al.,	  2010 plasma n=32	  samples HR	  1H-­‐NMR DOWN:	  valine,	  leucine,	  isoleucine
human Bogdanov	  et	  al.	  2008 plasma n=25	  controls	  n=66	  patients LCECA	  HPLC UP:	  glutathione,	  	  2-­‐hydroxy-­‐2-­‐deoxyguanosine	  DOWN:	  uric	  acid




Spinocerebellar	  Ataxia MJDI	  mouse	  model	   Griffin	  et	  al.	  2004 brain n=5	  per	  group HR/HR-­‐MAS	  1H-­‐NMR	   UP:	  glutamine	  DOWN:	  gamma-­‐aminobutyric	  acid,	  choline,	  phosphocholine,	  lactate
human Blasco	  et	  al.,	  2013 CSF n=128	  controls	  n=66	  patients LC	  MS UP:	  pyruvate,	  ascorbate,	  acetone	  DOWN:	  acetate
human Kumar	  et	  al.,	  2010 plasma n=30	  controls	  n=25	  controls HR	  1H-­‐NMR UP:	  glutamate,	  acetate,	  acetone,	  beta-­‐hydroxybutyrate,	  formate	  DOWN:	  glutamine,	  
histamine,	  N-­‐acetyl	  derivatives
Motor	  Neuron	  Disease human	   Blasco	  et	  al.,	  2014 CSF n=86	  controls	  n=95	  patients HR	  1H-­‐NMR 2-­‐hydroxy-­‐isovaleric	  acid,	  valine,	  isoleucine,	  2-­‐oxo-­‐3-­‐methyl	  isovaleric	  acid,	  2-­‐
oxoisovaleric	  acid,	  isobutyric	  acid,	  threonine,	  tyrosine,	  phenylalanine,	  1-­‐methyl-­‐
histidine,	  histidine
CUMS	  model Chen	  et	  al.,	  2014 brain n=8	  per	  group GC-­‐MS UP:	  N-­‐acetylaspartate,	  β-­‐alanine	  DOWN:	  isoleucine,	  glycerol
human Kaddurah-­‐Daouk	  et	  al.	  2012 CSF n=18	  controls	  n=14	  depressed	  
n=14	  remitted
LCECA	  HPLC UP:	  5-­‐hydroxyindoleacetic	  acid,	  tyrosine/hydroxyphenyllactate,	  methionine,	  
glutathione/methionine,	  xanthine/homovanillic	  acid,	  homovanillic	  acid/5-­‐
hydroxyindoleacetic	  acid	  	  DOWN:	  5-­‐hydroxyindoleacetic	  acid/tryptophane,	  5-­‐
hydroxyindoleacetic	  acid/kynurenine,	  xanthine	  methionine,	  	  homovanillic	  acid
MDD	  rat	  models Shi	  et	  al.,	  2013 plasma n=9	  per	  group HR	  1H-­‐NMR CUMS	  model	  UP:	  trimethylamine,	  aspartic	  acid,	  glutamate,	  acetoacetic	  acid,	  N-­‐acetyl	  
glycoproteins,	  	  β-­‐alanine,	  lactate,	  leucine,	  isoleucine,	  lipids	  DOWN:	  proline,	  β-­‐
hydroxybutyrate,	  valine;	  FST-­‐1d	  model	  DOWN:	  trimethylamine;	  FST-­‐14d	  model	  UP:	  α-­‐
glucose,	  β-­‐glucose,	  β-­‐hydroxybutyrate,	  valine,	  lipids	  
human Paige	  et	  al.,	  2007 plasma n=9	  controls	  n=10	  patients GC-­‐MS DOWN:	  gamma-­‐aminobutyric	  acid,	  stearate,	  3-­‐hydroxybutanoic	  acid,	  glycerol
human	  post	  mortem	   Lan	  et	  al.,	  2009 brain n=10	  controls	  n=10	  patients HR-­‐MAS	  1H-­‐NMR UP:	  lactate,	  phosphocholine,	  creatine,	  myo-­‐inositol,	  glutamate	  DOWN:	  
polyinsaturated	  lipids
human	  post	  mortem	   Schwarz	  et	  al.,	  2008 brain n=15	  controls	  n=15	  patients UPLC-­‐MS Grey	  matter:	  phosphatidylcholines	  (12	  sp.),	  palmitic	  acid,	  heptadecanoic	  acid,	  oleic	  
acid	  White	  matter:	  phosphatidylcholines	  (12	  sp.),	  linoleic	  acid,	  oleic	  acid,	  ceramides	  
(3	  sp.)	  Red	  blood	  cells:	  stearic	  acid,	  linoleic	  acid
human Sussulini	  et	  al.,	  2012 plasma n=25	  controls	  n=25	  patients HR	  1H-­‐NMR acetate,	  valine,	  proline,	  glutamate,	  glutamine,	  asparagine,	  lysine,	  choline,	  arginine,	  
proline,	  myo-­‐inositol,	  arginine,	  lipids	  (VLDL),	  lipoproteins,	  lactate,	  acetate
phencyclidine	  rat	  model Weisseling	  et	  al.,	  2013 brain n=8	  per	  group HR	  1H-­‐NMR DOWN:	  choline,	  glutamine,	  glutamate,	  glycine,	  taurine
human	  post	  mortem	   Prabakaran	  et	  al.	  2004 brain n=10	  controls	  n=10	  patients HR-­‐MAS	  1H-­‐NMR Prefrontal	  cortex	  UP:	  lipid,	  taurine,	  glutamate/glutamine,	  lactate	  DOWN:	  adenosine,	  
uridine,	  myo-­‐inositol,	  phosphocholine,	  acetate,	  gamma-­‐aminobutyric	  acid
human	  post	  mortem	   Schwarz	  et	  al.,	  2008 brain/red	  blood	  cells n=15	  controls	  n=15	  patients UPLC-­‐MS Grey	  matter:	  phosphatidylcholines	  (10	  sp.),	  palmitic	  acid,	  stearic	  acid	  White	  matter:	  
phosphatidylcholines	  (6	  sp.),	  palmitic	  acid,	  stearic	  acid,	  heptadecanoic	  acid,	  oleic	  
acid,	  ceramides	  (3	  sp.)	  Red	  blood	  cells:	  DOWN:	  stearic	  acid,	  linoleic	  acid,	  arachidonic	  
acid,	  ceramide	  (1	  sp.),	  palmitic	  acid,	  oleic	  acid
human	  post	  mortem	   Chan	  et	  al.,	  2011 brain n=10	  controls	  n=10	  patients LC-­‐MS Prefrontal	  cortex	  UP:	  glutamine,	  creatine	  DOWN:	  valine,	  leucine,	  isoleucine,	  alanine
human	   Holmes	  et	  al.	  2006a CSF n=70	  controls	  n=37	  (cohort	  1)	  
n=17	  (cohort	  2)	  patients
HR	  1H-­‐NMR UP:	  glucose	  DOWN:	  acetate,	  lactate,	  glutamine	  (pH	  shift),	  alanine	  (pH	  shift)
human	   Cai	  et	  al.	  2012 plasma/urine n=11	  controls	  n=11	  patients UPLC-­‐MS/	  HR	  1H-­‐NMR Plasma	  UP:	  lactate,	  alanine,	  glycine,	  lysophosphatidylcholine	  (4	  sp.)	  DOWN:	  
lipoproteins,	  3-­‐hydroxybutyrate,	  phosphatidylcholine	  (1	  sp.),	  acetoacetate,	  glucose,	  
LDL/VLDL/HDL,	  	  uric	  acid,	  unsaturated	  fatty	  acids	  Urine	  UP:	  glycine,	  valine,	  glucose,	  
uric	  acid,	  pregnanediol	  DOWN:	  creatine,	  creatinine,	  taurine,	  hippurate,	  
trimethylamine-­‐N-­‐oxide,	  citrate,	  alpha-­‐ketoglutarate
human	   Yao	  et	  al.,	  2010a,	  2010b plasma n=30	  controls	  n=25	  patients LCECA	  HPLC UP:	  xanthosine/guanine,	  N-­‐acetylserotonin,	  N-­‐acetylserotonin/tryptophane,	  
melatonin/serotonin	  DOWN:	  guanine/guanosine,	  	  uric	  acid/guanosine,	  uric	  
acid/xanthosine,	  melatonin/N-­‐acetylserotonin
Rett	  Syndrome Mecp2-­‐KO	  mouse	  model	   Viola	  et	  al.,	  2007 brain n=4	  per	  group HR	  1H-­‐NMR UP:	  glutamine	  DOWN:	  myo-­‐inositol,	  phosphocholine/	  glycerophosphocholine,	  
glutamine/glutamate
Fragile	  X	  Syndrome Fmr1-­‐KO	  mouse	  model	   Davidovic	  et	  al.,	  2011 brain n=10	  per	  group HR-­‐MAS	  1H-­‐NMR UP:	  acetotacetate,	  CH2-­‐CO/CH2-­‐CH2-­‐CH2-­‐CO,	  taurine,	  creatine,	  beta-­‐amino	  butyrat	  
DOWN:	  lactate,	  glutamine,	  gamma-­‐aminobutyric	  acid,	  N-­‐acetyl-­‐aspartate,	  glutamate,	  
myo-­‐inositol,	  aspartate,	  acetate,	  N,N,N-­‐trimethyl-­‐lysine,	  alanine,	  kynurenine,	  N-­‐alpha-­‐
acetylornithine,	  adenine,	  inosine,	  purine,	  ethanolamine
maternal	  immune	  activation	  
ASD	  mouse	  model	  
Hsiao	  et	  al.,	  2013 plasma n=10/group GC/LC-­‐MS UP:	  4-­‐ethylphenylsulfate,	  ribose	  DOWN:	  	  3-­‐methyl-­‐2-­‐oxovalerate,	  4-­‐methyl-­‐
oxopentanoate,	  	  glycylvaline,	  equolsulfate,	  eicosenoate,	  stearate,	  13-­‐
hydroxyoctadecadienoic	  acid,	  9-­‐hydroxyoctadecadienoic	  acid,	  octadecanedioate,	  12-­‐
hydroxyeicosatetraenoic	  acid,	  1-­‐palmitoylplasmenylethanolamine,	  1-­‐
stearoylglycerophosphoinositol
human Yap	  et	  al.,	  2010 urine n=34	  controls	  n=39	  patients HR	  1H-­‐NMR UP:	  acetate,	  dimethylamine,succinate,	  taurine,	  N-­‐methyl	  nicotinic	  acid,	  N-­‐methyl	  
nicotinamide,	  N-­‐methyl-­‐2-­‐pyridone-­‐5-­‐carboxamide	  	  DOWN:	  glutamate,	  hippurate,	  
phenylacetylglutamine
human Emond	  et	  al.,	  2013 urine n=24	  controls	  n=26	  patients GC-­‐MS UP:	  succinate,	  glycolate	  DOWN:	  hippurate,	  3-­‐hydroxyphenylacetate,	  
vanillylhydracrylate,	  3-­‐hydroxy-­‐hippurate,	  p-­‐hydroxy	  mandelate,	  1H-­‐indole-­‐3-­‐acetate,	  
palmitate,	  stearate,	  3-­‐methyladipate
Down	  Syndrome human Bahado-­‐Singh	  et	  al.	  2013 1st	  trimester	  
pregnant	  woman	  
plasma
n=60	  controls	  n=30	  patients HR	  1H-­‐NMR UP:	  2-­‐/3-­‐hydroxybutyrate,	  	  2-­‐hydroxyisovalerate,	  acetamide	  acetone,	  carnitine,	  

















Salek	  et	  al.	  2010 HR	  1H-­‐NMR UP:	  lactate,	  aspartate,	  glycine,	  alanine,	  leucine,	  isoleucine,	  valine,	  fatty	  acids	  	  	  	  	  	  	  	  	  
DOWN:	  N-­‐acetylaspartate,	  glutamate,	  glutamine,	  taurine,	  gamma-­‐aminobutyric	  acid,	  
choline,	  phosphocholine,	  creatine,	  phosphocreatine,	  succinate
brain n=5	  per	  groupCRND8	  mouse	  model	  
Neurodevelopmental	  
disorders
Enriched	  metabolic	  pathway SMPDB	  or	  KEGG	  ID AD HD NCL MND MDD SCZ FXS
Alanine	  metabolism SMP00055 ✓ ✓ ✓
Alanine,	  aspartate	  and	  glutamate	  metabolism	   map00250 ✓ ✓
Arginine	  and	  proline	  metabolism	   SMP00020 ✓ ✓ ✓
Cysteine	  metabolism SMP00013 ✓
Glycine,	  serine	  and	  threonine	  metabolism map00260 ✓
Methionine	  metabolism SMP00033 ✓ ✓
Valine,	  leucine,	  isoleucine	  degradation SMP00032 ✓ ✓ ✓
Histidine	  metabolism SMP00044 ✓
D-­‐Glutamine	  and	  D-­‐glutamate	  metabolism map00471 ✓ ✓ ✓
Glutamate	  metabolism SMP00072 ✓ ✓ ✓
Catecholamine	  biosynthesis SMP00012 ✓
Tyrosine	  metabolism SMP00006 ✓
Phenylalanine	  and	  tyrosine	  metabolism SMP00008 ✓ ✓
Tryptophan	  metabolism SMP00063 ✓ ✓
Taurine	  and	  hypotaurine	  metabolism SMP00021 ✓
Gluconeogenesis SMP00128 ✓
Ketone	  body	  metabolism SMP00071 ✓
Pyruvate	  metabolism SMP00060 ✓ ✓
Urea	  cycle SMP00059 ✓
Pyrimidine	  metabolism SMP00046 ✓
Aminoacyl-­‐tRNA	  biosynthesis	   map00970 ✓
Ammonia	  recycling	   SMP00009 ✓ ✓
Betaine	  metabolism SMP00123 ✓
Neurodegenerative	  disorders Psychiatric	  disorders
Amino	  acids
Neurotransmitters	  
Energy	  substrates
Other



